» Articles » PMID: 553832

[3-Hydrazinepyridazine Derivatives. III. Synthesis and Anti-hypertensive Activity of New 3-(2-acylhydrazine)-pyridazine-6-alkylamino Substitutes]

Overview
Journal Farmaco Sci
Specialties Pharmacology
Pharmacy
Date 1979 Apr 1
PMID 553832
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The synthesis of 2-(6-dialkylamino-3-pyridazinyl)hydrazinecarboxylates (II) and hydrazides (V) from the corresponding 3-chloro-6-dialkylaminopyridazines (I) is described. The 6-substituted derivatives of 2,3-dihydro-1,2,4-triazolo[4,3-b]pyridazine-3-ones (III) and 1,2,4-triazolo[4,3-b)pyridazines (VI) were obtained by thermal cyclization of (II) and (V), respectively. The new acyl derivatives were evaluated together with todralazine and budralazine as antihypertensive agents in comparison with propildazine and hydralazine. The ethoxycarbonyl compound [(II g), ISF 2469] exhibits good antihypertensive activity particularly via oral administration. Its interesting pharmacodynamic properties, including slow onset and long-lasting action, qualify it for further pharmacological and clinical studies.

Citing Articles

Studies on the metabolism of cadralazine in rat.

Simonotti L, Zanol M, Parravicini F, PIFFERI G Eur J Drug Metab Pharmacokinet. 1982; 7(1):39-45.

PMID: 7067722 DOI: 10.1007/BF03189541.


[14C]cadralazine: absorption, distribution and excretion in rat and dog.

Bonardi G, Rossi E, Pellegatti M Eur J Drug Metab Pharmacokinet. 1983; 8(1):25-33.

PMID: 6861793 DOI: 10.1007/BF03189578.


Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.

Catalano M, Parini J, Romano M, LIBRETTI A Eur J Clin Pharmacol. 1985; 28(2):135-8.

PMID: 3886402 DOI: 10.1007/BF00609680.


Cadralazine did not produce the SLE-syndrome when hydralazine did.

Andersson O Eur J Clin Pharmacol. 1987; 31(6):741.

PMID: 3556384 DOI: 10.1007/BF00541309.